SecBot SecBot
Biotech Drug Report Generated Nov 6, 2026

PIPE-307

CTNM·Contineum Therapeutics, Inc.
BEARISH
Drug Impact Rating3/10
Trial phase
Phase 2 (failed)
Time to market
Uncertain. J&J is evaluating exploratory data to decide whether to continue development. With two Phase 2 failures in different indications, the program's path to approval is highly uncertain and likely several years away if development continues at all.
Why 3/10
No hard dated binary catalyst is scheduled for PIPE-307 in the next ~12 months. J&J is evaluating exploratory data from the failed MOONLIGHT-1 trial but has not announced a decision date. The drug has already failed two Phase 2 trials, removing any near-term binary event. The company's focus has shifted to its wholly owned PIPE-791 program.
Actionable Insight BEARISH

Watch for J&J's decision on PIPE-307's future, which could come at any time. A termination would remove any remaining upside from milestone payments and royalties, while a decision to continue into another trial would be a modest positive surprise. The more consequential catalyst for CTNM as a whole is the ongoing Phase 2 PROPEL-IPF trial of PIPE-791 (completion expected June 2028), but that is years away.

Price Chart

Loading chart...

Executive Summary

PIPE-307 is an oral M1 muscarinic receptor antagonist being developed by Contineum Therapeutics (Nasdaq: CTNM) in partnership with Johnson & Johnson. The drug has failed two Phase 2 clinical trials: the VISTA trial in relapsing-remitting multiple sclerosis (November 2025) and the MOONLIGHT-1 trial in major depressive disorder (September 2026). Both missed their primary efficacy endpoints, though safety was acceptable. J&J is now evaluating exploratory data to determine the program's future, with no announced decision date. Contineum holds $244.5M in cash (runway through mid-2029) and has shifted strategic focus to its wholly owned PIPE-791 program for idiopathic pulmonary fibrosis.

How It Works

PIPE-307 is an oral small molecule that blocks the M1 muscarinic receptor (M1R) in the brain. By blocking this receptor, the drug aims to promote the repair of myelin (the protective coating around nerve fibers) in multiple sclerosis, and was also tested for its potential antidepressant effects in major depressive disorder.

Trial Status

PIPE-307 has completed two Phase 2 trials, both of which failed to meet their primary efficacy endpoints. The Phase 2 VISTA trial (NCT06083753) in relapsing-remitting multiple sclerosis (RRMS) enrolled 168 patients and missed its primary endpoint of change in binocular low contrast letter acuity, as well as all secondary efficacy endpoints (topline reported November 20, 2025). The Phase 2 MOONLIGHT-1 trial (NCT06785012) in major depressive disorder (MDD) also failed to meet its primary endpoint of improvement in MADRS total score at Day 5 versus placebo (topline reported September 14, 2026). Both trials showed acceptable safety and tolerability.

The Two-Sided Case

▲ Bull Case3
J&J licensed PIPE-307 in 2023 for $50M upfront plus $25M equity investment, with over $1B in potential milestones and tiered royalties, signaling strong pharma validation of the M1R mechanism
Both Phase 2 trials demonstrated acceptable safety and tolerability at both doses tested, leaving room for a different dosing regimen or patient population to be explored
Analyst consensus remains a Buy (6 Buy/5 Strong Buy vs 3 Hold), with a mean price target of $22.14 implying ~147% upside from the $8.97 reference price as of November 5, 2026
▼ Bear Case4
PIPE-307 has failed to meet efficacy endpoints in two separate Phase 2 trials across two different indications (RRMS and MDD), raising fundamental questions about the M1R antagonism mechanism
J&J is reviewing exploratory data with no announced timeline for a decision; the program could be terminated entirely, eliminating any future milestone or royalty revenue for Contineum
Key institutional holders including Baker Bros. Advisors and RA Capital Management exited their positions entirely in Q2 2026, and Baird downgraded the stock to Neutral in October 2026
Short interest has risen to 9.72% of outstanding shares as of October 15, 2026, and short-sale volume is elevated relative to the stock's own history (z-score 1.99)

Upcoming Catalysts

  • J&J decision on whether to continue PIPE-307 development (no date announced)
  • Q3 2026 earnings call on November 11, 2026 (company-level catalyst, not drug-specific)

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Contineum Therapeutics, Inc. 8-K CTNM ·Originating report

Sources · 10

Hover a chip for the title
1 ir.contineum-tx.com2 ir.contineum-tx.com3 fiercebiotech.com4 fiercebiotech.com5 biospace.com6 businesswire.com7 pnas.org8 contineum-tx.com9 neurologylive.com10 clinicaltrials.gov